Clinical trial · Interventional
Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal
Efficacy and Safety of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal. Phase II Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A randomized, double-blind, phase II clinical trial was conducted versus placebo in 110 patients with esophageal human papillomavirus. The experimental group will receive the VIUSID® plus GLIZIGEN® nutritional supplements, administered on an outpatient basis for 3 months. The control group will receive placebo from Viusid plus Glizigen placebo. It is expected that patients in the experimental group have a 30% higher rate of elimination of the virus than patients in the placebo group after treatment. The study will be conducted in the Superior Digestive Tract consultation of the Institute of Gastroenterology of Havana, Cuba.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Verrucous Carcinoma | Esophageal Verrucous Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Esophageal Viral Wart | — | UNRESOLVED | — |
| Papilloma Viral Infection | — | UNRESOLVED | — |
| Papillomavirus Infections | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Glizigen® | Dietary Supplement | — | UNRESOLVED |
| Glizigen Placebo | Dietary Supplement | — | UNRESOLVED |
| Viusid® | Dietary Supplement | — | UNRESOLVED |
| Viusid Placebo | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Viusid® + Glizigen®
- description
- The experimental arm will receive nutritional supplements Viusid + Glizigen
- interventionNames
- Dietary Supplement: Viusid®
- Dietary Supplement: Glizigen®
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- The control group will receive a placebo of both (Viusid and Glizigen).
- interventionNames
- Dietary Supplement: Viusid Placebo
- Dietary Supplement: Glizigen Placebo
Primary outcomes (2)
- measure
- Clinical improvement of the lesions of the virus in esophageal mucosal tissue sample
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Older adults between 18 and 65 years of both sexes. * Patients residing in the provinces of Havana, Artemisa and Mayabeque. * Voluntariness of the patient to participate in the study. Informed and written consent. * Women of childbearing age should have negative pregnancy test or use effective contraceptive methods such as intrauterine devices, hormonal contraceptives, barrier method or tubal ligation. Exclusion Criteria: * Pregnancy or breastfeeding. * Contraindication to the performance of upper digestive endoscopy. * Psychiatric conditions that do not favor the administration of treatment and follow-up. * History of hypersensitivity to another similar product. * Severe acute allergic states. * Patients with concomitant diagnosis of esophageal tumor or other causes of infectious esophagitis. * Present an associated chronic illness in the decompensation phase (heart disease, diabetes, hypertension, renal failure, AIDSl). * Patients who are receiving another product under investigation.
References
Publications (0)
Data not yet available